Moderna clinical trial data confirm its updated covid-19 vaccine generates robust immune response in humans against widely circulating variants

Updated covid-19 vaccine effectively targets eg.5, a dominant variant of concern, as well as the rapidly spreading fl 1.5.1 variant updated vaccine expected to be available, pending approval, in coming weeks for fall vaccination season cambridge, ma / accesswire / august 17, 2023 / moderna, inc. (nasdaq:mrna) today announced that preliminary clinical trial data confirm its updated covid-19 vaccine for the fall 2023 vaccination season showed a significant boost in neutralizing antibodies against eg.5 and fl.1.5.1 variants. these results suggest that moderna's updated covid-19 vaccine may effectively target the expected circulating variants of covid-19 during the upcoming vaccination season.
MRNA Ratings Summary
MRNA Quant Ranking